Cook's Zilver stent recall could be a costly one

Cook Medical's ongoing recall of its Zilver PTX stent could be a costly one. While the company isn't commenting on how many stents it has recalled since the FDA slapped its most serious "Class I" status on the effort late last month, the product has been deployed in more than 30,000 patients internationally since its 2009 overseas approval, according to company data cited by The Indianapolis Business Journal. The article also notes Millennium Research Group estimates that point to the stent generating $2,750 per U.S. sale. Zilver just gained U.S. approval last November. Millennium estimates Zilver could sell 40,000 units annually just in the U.S., producing $100 million in annual revenue. It is the first drug-eluting stent cleared in the U.S. to treat peripheral artery disease. Story

Suggested Articles

BD will begin working with Babson Diagnostics to help bring its lab-quality device for collecting blood from capillaries into retail pharmacies.

The former CEO of the molecular testing company Foundation Medicine, Troy Cox, has been named chairman of the Swiss big data firm Sophia Genetics.

Researchers at MIT used a machine-learning algorithm to uncover the potent antibiotic properties hiding within an old small-molecule candidate.